Teva Pravachol Exclusivity Loss Raises Bristol’s Stakes For Switch
This article was originally published in The Tan Sheet
Executive Summary
Bristol-Myers Squibb has more to gain from an Rx-to-OTC switch of the cholesterol-lowering drug Pravachol (pravastatin) if an FDA decision allowing multiple generics on the market in April 2006 is upheld
You may also be interested in...
Teva Entitled To Exclusivity Period For Generic Pravachol – D.C. Court
Teva's 180-day marketing exclusivity period for its generic equivalent of Bristol-Myers Squibb's Rx Pravachol (pravastatin) has "neither expired nor even commenced," District of Columbia District Court ruled Oct. 21
Teva Entitled To Exclusivity Period For Generic Pravachol – D.C. Court
Teva's 180-day marketing exclusivity period for its generic equivalent of Bristol-Myers Squibb's Rx Pravachol (pravastatin) has "neither expired nor even commenced," District of Columbia District Court ruled Oct. 21
Teva Entitled To Exclusivity Period For Generic Pravachol – D.C. Court
Teva's 180-day marketing exclusivity period for its generic equivalent of Bristol-Myers Squibb's Rx Pravachol (pravastatin) has "neither expired nor even commenced," District of Columbia District Court ruled Oct. 21